Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1025

1.

New and important changes in breast cancer TNM: incorporation of biologic factors into staging.

Edge SB, Hortobagyi GN, Giuliano AE.

Expert Rev Anticancer Ther. 2019 Feb 13. doi: 10.1080/14737140.2019.1582335. [Epub ahead of print]

PMID:
30759347
2.

Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.

Prat A, Brase JC, Cheng Y, Nuciforo P, Paré L, Pascual T, Martínez D, Galván P, Vidal M, Adamo B, Hortobagyi GN, Baselga J, Ciruelos E.

Oncologist. 2019 Jan 24. pii: theoncologist.2018-0407. doi: 10.1634/theoncologist.2018-0407. [Epub ahead of print]

PMID:
30679318
3.

Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.

Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V.

Invest New Drugs. 2019 Jan 5. doi: 10.1007/s10637-018-0700-z. [Epub ahead of print]

PMID:
30610588
4.

Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221).

Mongiovi JM, Zirpoli GR, Cannioto R, Sucheston-Campbell LE, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Thomas Budd G, Albain KS, Ambrosone CB, McCann SE.

Breast Cancer Res. 2018 Nov 28;20(1):146. doi: 10.1186/s13058-018-1077-9.

5.

Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial.

Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, Buchholz D, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Amaya DN, Shen Y, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD.

J Clin Oncol. 2018 Oct 31:JCO1800317. doi: 10.1200/JCO.18.00317. [Epub ahead of print]

PMID:
30379626
6.

Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230.

Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS.

J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185.

PMID:
30371800
7.

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?

Yam C, Hung MC, Hortobagyi GN.

Oncotarget. 2018 Sep 28;9(76):34193-34195. doi: 10.18632/oncotarget.26134. eCollection 2018 Sep 28. No abstract available.

8.
9.

A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.

Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC Jr, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B.

Invest New Drugs. 2018 Dec;36(6):1103-1109. doi: 10.1007/s10637-018-0672-z. Epub 2018 Oct 11.

PMID:
30311036
10.

Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing.

Hortobagyi GN, Zheng M, Mohanlal R.

Oncologist. 2019 Feb;24(2):178-184. doi: 10.1634/theoncologist.2018-0218. Epub 2018 Oct 8.

PMID:
30297386
11.

American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions.

Hortobagyi GN, Pyle D, Cazap EL, El Saghir NS, Shulman LN, Lyman GH, Schnipper LE, Adebamowo CA, Gandara DR, Vose J, Wong SL, Yu P.

J Glob Oncol. 2018 Sep;(4):1-8. doi: 10.1200/JGO.17.00060. Epub 2017 Aug 11.

12.

New and Important Changes in the TNM Staging System for Breast Cancer.

Hortobagyi GN, Edge SB, Giuliano A.

Am Soc Clin Oncol Educ Book. 2018 May 23;(38):457-467. doi: 10.1200/EDBK_201313. Review.

PMID:
30231399
13.

Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.

Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL.

Oncologist. 2018 Nov;23(11):1300-1309. doi: 10.1634/theoncologist.2017-0498. Epub 2018 Aug 23.

PMID:
30139837
14.

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.

Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN.

Oncologist. 2018 Nov;23(11):1282-1288. doi: 10.1634/theoncologist.2018-0085. Epub 2018 Aug 17.

PMID:
30120166
15.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J.

Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155.

PMID:
29718092
16.

Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.

Giuliano AE, Edge SB, Hortobagyi GN.

Ann Surg Oncol. 2018 Jul;25(7):1783-1785. doi: 10.1245/s10434-018-6486-6. Epub 2018 Apr 18. No abstract available.

PMID:
29671136
17.

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.

Pelekanou V, Barlow WE, Nahleh ZA, Wasserman B, Lo YC, von Wahlde MK, Hayes D, Hortobagyi GN, Gralow J, Tripathy D, Porter P, Szekely B, Hatzis C, Rimm DL, Pusztai L.

Mol Cancer Ther. 2018 Jun;17(6):1324-1331. doi: 10.1158/1535-7163.MCT-17-1005. Epub 2018 Mar 27.

PMID:
29588392
18.

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK.

Cancer. 2018 Jun 1;124(11):2299-2305. doi: 10.1002/cncr.31336. Epub 2018 Mar 26.

PMID:
29579338
19.

Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.

Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx098.

20.

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC.

Cancer Cell. 2018 Feb 12;33(2):187-201.e10. doi: 10.1016/j.ccell.2018.01.009.

21.

Characterization of bone only metastasis patients with respect to tumor subtypes.

Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, Hortobagyi GN.

NPJ Breast Cancer. 2018 Jan 25;4:2. doi: 10.1038/s41523-018-0054-x. eCollection 2018.

22.

A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.

Yam C, Murthy RK, Valero V, Szklaruk J, Shroff GS, Stalzer CJ, Buzdar AU, Murray JL, Yang W, Hortobagyi GN, Moulder SL, Arun B.

Invest New Drugs. 2018 Apr;36(2):299-306. doi: 10.1007/s10637-018-0564-2. Epub 2018 Jan 27.

PMID:
29374384
23.

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).

Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, Tripathy D, Hortobagyi GN, Hayes DF.

Ann Oncol. 2018 Mar 1;29(3):654-660. doi: 10.1093/annonc/mdx821.

PMID:
29293876
24.

Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB.

Pharmacogenet Genomics. 2018 Feb;28(2):49-55. doi: 10.1097/FPC.0000000000000318.

25.

Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.

Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, Hortobagyi GN, Valero V.

Br J Cancer. 2018 Jan;118(1):17-23. doi: 10.1038/bjc.2017.379. Epub 2017 Dec 12.

26.

Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA.

JAMA Oncol. 2018 Feb 1;4(2):203-209. doi: 10.1001/jamaoncol.2017.4298.

27.

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer-Reply.

Hortobagyi GN, Zheng M.

JAMA Oncol. 2018 Apr 1;4(4):586. doi: 10.1001/jamaoncol.2017.3868. No abstract available.

PMID:
29192319
28.

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.

O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GN.

Breast Cancer Res Treat. 2018 Feb;168(1):127-134. doi: 10.1007/s10549-017-4518-8. Epub 2017 Nov 21.

29.

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes.

Masuda H, Qi Y, Liu S, Hayashi N, Kogawa T, Hortobagyi GN, Tripathy D, Ueno NT.

Oncotarget. 2017 Jul 31;8(41):70481-70495. doi: 10.18632/oncotarget.19719. eCollection 2017 Sep 19.

30.

EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer.

Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA Jr, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT.

Oncotarget. 2017 Jul 4;8(40):67904-67917. doi: 10.18632/oncotarget.18958. eCollection 2017 Sep 15.

31.

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.

Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC.

Oncogene. 2018 Jan 11;37(2):208-217. doi: 10.1038/onc.2017.311. Epub 2017 Sep 18.

32.

Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status.

Hayashi N, Iwamoto T, Qi Y, Niikura N, Santarpia L, Yamauchi H, Nakamura S, Hortobagyi GN, Pusztai L, Symmans WF, Ueno NT.

J Cancer. 2017 Apr 9;8(6):1045-1052. doi: 10.7150/jca.13690. eCollection 2017.

33.

Ultrasound Molecular Imaging: A Good Start.

Whitman GJ, Hortobagyi GN.

J Clin Oncol. 2017 Jul 1;35(19):2101-2102. doi: 10.1200/JCO.2016.71.9997. Epub 2017 May 12. No abstract available.

PMID:
28498783
34.

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.

Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT.

Breast Cancer Res Treat. 2017 Jul;164(1):57-67. doi: 10.1007/s10549-017-4233-5. Epub 2017 Apr 17.

PMID:
28417335
35.

Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.

Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw314.

36.

Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT.

Lancet Oncol. 2017 Apr;18(4):e228-e232. doi: 10.1016/S1470-2045(17)30192-4. Review.

37.

Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, Weaver DL, Winchester DJ, Hortobagyi GN.

CA Cancer J Clin. 2017 Jul 8;67(4):290-303. doi: 10.3322/caac.21393. Epub 2017 Mar 14. Erratum in: CA Cancer J Clin. 2017 Jul 8;67(4):345.

38.

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.

Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, Baselga J, Chandarlapaty S.

Br J Cancer. 2017 Mar 14;116(6):726-730. doi: 10.1038/bjc.2017.25. Epub 2017 Feb 9.

39.

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC.

Clin Cancer Res. 2017 Jul 15;23(14):3711-3720. doi: 10.1158/1078-0432.CCR-16-3215. Epub 2017 Feb 6.

40.

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN.

J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30.

41.

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.

Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A.

JAMA Oncol. 2017 Jul 1;3(7):906-912. doi: 10.1001/jamaoncol.2016.6316.

42.

Ribociclib for HR-Positive, Advanced Breast Cancer.

Hortobagyi GN.

N Engl J Med. 2017 Jan 19;376(3):289. doi: 10.1056/NEJMc1615255. No abstract available.

PMID:
28099830
43.

Current challenges of metastatic breast cancer.

Lim B, Hortobagyi GN.

Cancer Metastasis Rev. 2016 Dec;35(4):495-514. doi: 10.1007/s10555-016-9636-y. Review.

PMID:
27933405
44.

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K.

Clin Cancer Res. 2017 Jun 15;23(12):2991-3002. doi: 10.1158/1078-0432.CCR-16-2217. Epub 2016 Nov 23.

45.

Deubiquitination and Stabilization of PD-L1 by CSN5.

Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC.

Cancer Cell. 2016 Dec 12;30(6):925-939. doi: 10.1016/j.ccell.2016.10.010. Epub 2016 Nov 17.

46.

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J.

N Engl J Med. 2016 Nov 3;375(18):1738-1748. Epub 2016 Oct 7. Erratum in: N Engl J Med. 2018 Dec 27;379(26):2582.

47.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

48.

Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.

Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.

Nat Med. 2016 Oct 6;22(10):1192. doi: 10.1038/nm1016-1192c. No abstract available.

PMID:
27711065
49.

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.

Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC.

Nat Commun. 2016 Aug 30;7:12632. doi: 10.1038/ncomms12632.

50.

Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer.

Harano K, Lei X, Gonzalez-Angulo AM, Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN, Chavez-MacGregor M.

Breast Cancer Res Treat. 2016 Sep;159(2):367-74. doi: 10.1007/s10549-016-3933-6. Epub 2016 Aug 13.

PMID:
27522517

Supplemental Content

Loading ...
Support Center